Inactive Instrument

Analyst Reco. DelMar Pharmaceuticals Inc Nasdaq

Equities

Maxim Upgrades Kintara Therapeutics to Buy From Hold With $14 Price Target	23-07-14	MT
Maxim Downgrades Kintara Therapeutics to Hold From Buy	22-09-29	MT
Dawson James Downgrades Kintara Therapeutics to Neutral From Buy	22-05-16	MT
Maxim Group Adjusts Kintara Therapeutics Price Target to $1.50 From $3, Maintains Buy Rating	22-02-02	MT
HC Wainwright Adjusts Kintara Therapeutics' Price Target to $3 From $6, Keeps Buy Rating	22-01-20	MT
KINTARA THERAPEUTICS : Aegis Capital Adjusts Price Target on Kintara Therapeutics to $5 From $7, Maintains Buy Rating	21-09-30	MT
KINTARA THERAPEUTICS : HC Wainwright Starts Kintara Therapeutics at Buy	21-09-28	MT

No results for this search